Prometic Life Scie Com Npv (PFSCF) Downgraded to Hold at Zacks Investment Research

Zacks Investment Research cut shares of Prometic Life Scie Com Npv (NASDAQ:PFSCF) from a buy rating to a hold rating in a research note issued to investors on Wednesday.

According to Zacks, “ProMetic Life Sciences Inc. is a biopharmaceutical company. The company is involved in bioseparations, plasma-derived therapeutics and small-molecule drug development. Its operating segment consists of Therapeutics and Protein Technology. Therapeutics segment products include PBI-4050 for treatment of fibrosis with chronic kidney diseases, certain cancers and side effects associated with chemotherapy; PBI-4419, an anti-fibrotic and anti-inflammatory compound for kidney injury and chronic kidney diseases and PBI-1402 for the treatment of anemia indications. Protein Technology segment provides plasma protein purification system, bioseparation products and prion capture/pathogen removal technology platform. ProMetic Life Sciences Inc. is headquartered in Laval, Canada. “

Prometic Life Scie Com Npv (NASDAQ:PFSCF) traded up 1.5630% on Wednesday, reaching $2.3977. 7,856 shares of the company’s stock traded hands. Prometic Life Scie Com Npv has a 52-week low of $1.29 and a 52-week high of $2.77. The stock’s market capitalization is $1.45 billion. The firm’s 50-day moving average is $2.23 and its 200 day moving average is $2.33.

5 Day Chart for NASDAQ:PFSCF

Get a free copy of the Zacks research report on Prometic Life Scie Com Npv (PFSCF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Prometic Life Scie Com Npv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prometic Life Scie Com Npv and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.